The purpose of this trial is to study the effect of initial temporary sevoflurane sedation on
mortality and persistent organ dysfunction (POD) in survivors at day 28 after ICU admission
in the population of patients suffering from COVID-19 ARDS.
Phase:
Phase 3
Details
Lead Sponsor:
University of Zurich
Collaborators:
Cantonal Hospital of St. Gallen Kantonsspital Münsterlingen Triemli Hospital